BioAtla-JPM-202401.pdf

1、Corporate PresentationJanuary 2024Conditionally Active Biologics:Transforming Cancer TherapyBioAtla|Overview 2Important Notices&DisclaimersThis presentation(the“Presentation”)by BioAtla,Inc.(“we”,“us”,“our”,“BioAtla”,or the“Company”)contains“forward-looking statements”within the meaning of the Priva

2、te Securities Litigation Reform Act of 1995 relating to our business,operations and financial conditions,including but not limited to statements regarding business plans and prospects and whether our clinical trials will support registration;achievement of milestones;results,conduct,progress and tim

3、ing of our research and development programs and clinical trials;expectations with respect to enrollment and dosing in our clinical trials,plans and expectations regarding future data updates,clinical trials,regulatory meetings and regulatory submissions;plans to form collaborations or other strateg

4、ic partnerships for selected assets;the potential regulatory approval path for our product candidates;expectations about the sufficiency of our cash and cash equivalents and plans to prioritize and focus development on selected assets and indications.Words such as,but not limited to,“anticipate”,“be

5、lieve”,“could”,“estimate”,“expect”,“intend”,“may”,“plan”,“potential”,“predict”,“project”,“should”,“will”,“would”or the negative of those terms,and similar expressions that convey uncertainty of future events or outcomes,identify forward-looking statements.These forward-looking statements reflect man

6、agements beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this Presentation and are subject to risks and uncertainties,including those described in the Companys filings with the SEC,including but not limited to the Companys latest Quarterly